Cardiology

No improvements with losmapimod after heart attack

Patients taking losmapimod, an anti-inflammatory drug currently being developed, for 12 weeks following a heart attack did not show improvements in the trial's primary endpoint, the rate of cardiovascular death, subsequent ...

Cardiology

Evacetrapib fails to reduce major adverse cardiovascular events

Despite lowering low-density lipoprotein (LDL), known as "bad" cholesterol, while markedly increasing levels of high-density lipoprotein (HDL), or "good" cholesterol, a large clinical trial to investigate the cholesterol ...

Cardiology

The art of appropriate patient selection for heart procedures

A decline in the number of heart patients undergoing unnecessary PCI (angioplasty) procedures reflects improvements in clinical decision-making and documentation to determine which patients benefit most from the procedure, ...

page 14 from 31